Genentech Xenon MRI Idiopathic Pulmonary Fibrosis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

August 3, 2020

Primary Completion Date

October 17, 2024

Study Completion Date

September 30, 2029

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment

Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Idiopathic Pulmonary Fibrosis (IPF) patients receiving approved IPF treatments

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Duke University

OTHER